Takeda agrees deal with AC Immune for Alzheimer's program

13 May 2024
takeda_hq_japan_large

Japanese pharma major Takeda (TYO:4502) and Massachusetts, USA-based firm AC Immune (Nasdaq: ACIU) have inked a major new licensing deal.

The exclusive, worldwide option and license agreement relates to AC Immune’s active immunotherapies targeting toxic forms of amyloid beta.

Looking to make an impact in the growing area of Alzheimer’s disease treatment, Takeda will pick up rights to the immunotherapy ACI-24.060 through the deal.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology